Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsHoward Feldman, MD, FRCPC, FAAN (Neurology)
Professor AdjunctAbout
Copy Link
Research
Copy Link
Overview
Medical Research Interests
Dementia; Information Science; Named Groups
ORCID
0000-0002-9258-4538
Research at a Glance
Yale Co-Authors
Frequent collaborators of Howard Feldman's published research.
Publications Timeline
A big-picture view of Howard Feldman's research output by year.
Research Interests
Research topics Howard Feldman is interested in exploring.
James Brewer
Godfrey Pearlson, MA, MBBS
Vladimir Coric, MD
74Publications
924Citations
Publications
2025
Cognitive heterogeneity in mild cognitive impairment due to Alzheimer's disease pathology.
Chen S, Salmon D, Feldman H, Messer K, Bondi M, Xu D, Qiu Y, Jacobs D. Cognitive heterogeneity in mild cognitive impairment due to Alzheimer's disease pathology. Neural Regeneration Research 2025 PMID: 41169220, DOI: 10.4103/nrr.nrr-d-25-00308.Peer-Reviewed Original ResearchAltmetricConceptsCognitive impairmentMild cognitive impairmentCognitive heterogeneityCognitive subtypesCognitive profileAlzheimer's diseaseNeuropsychological test dataNon-memory measuresPattern of impairmentPattern of performanceNon-memory testsTypical groupMild Cognitive Impairment SubtypesRate of clinical declineCognitive impairment subtypesMild cognitive impairment due to Alzheimer’s diseaseImpairment subtypesCognitive variablesMemory testCognitive domainsMagnetic resonance imaging volumetric measurementsBrain regionsCerebrospinal fluid biomarkersCognitive testsBrain volumeAtomoxetine Drug Properties for Repurposing as a Candidate Alzheimer’s Disease Therapeutic Agent
Demsey L, Burch D, Lin E, Quach D, Podvin S, Boyarko B, Levey A, Weinshenker D, Edland S, Galasko D, Jacobs H, Bang A, Neil A, Silverman J, Feldman H, Hook V. Atomoxetine Drug Properties for Repurposing as a Candidate Alzheimer’s Disease Therapeutic Agent. ACS Pharmacology & Translational Science 2025, 8: 3757-3772. PMID: 41262573, PMCID: PMC12624433, DOI: 10.1021/acsptsci.5c00502.Peer-Reviewed Original ResearchAltmetricConceptsAttention deficit hyperactivity disorderEarly stages of ADNE transporterStages of ADLocus coeruleusTreatment of attention deficit hyperactivity disorderNeurotransmitter norepinephrineEffects of atomoxetineAlzheimer's diseaseDeficit hyperactivity disorderAD therapeuticsInhibitor atomoxetineCognitive symptomsExtracellular NEHyperactivity disorderAD biomarkersBrain regionsClinical drug trialsAD deficitsAtomoxetineNoradrenergic neuronsNeuroprotective effectsSynaptic deficitsCognitive declineAD therapeutic agentsRisk factor profiles and cognitive function in older adults: the Brain Health Support Program Study
Duchaine C, Montero‐Odasso M, Nygaard H, Brewster P, Jacobs D, Anderson N, Slack P, Durant J, Lupo J, Chertkow H, Feldman H, Belleville S, Aging C. Risk factor profiles and cognitive function in older adults: the Brain Health Support Program Study. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2025, 11: e70173. PMID: 41255551, PMCID: PMC12623131, DOI: 10.1002/trc2.70173.Peer-Reviewed Original ResearchConceptsAssociated with poorer cognitionModifiable risk factorsAssociated with cognitionRisk factorsOlder adultsPoor cognitionRisk profilePrevention strategiesDementia risk factorsRisk of dementiaVascular healthPoor vascular healthRisk factor profileCombination of risk factorsCognitive engagementDementia preventionPhysical activityLow cognitive engagementBetter dietsCanadian populationFactor profileHealthDementiaEngagement profilesCognitive functionAn International Working Group viewpoint on stratifying risk and prevention of the clinical expression of Alzheimer’s disease
Feldman H, Villain N, Frisoni G, Dubois B. An International Working Group viewpoint on stratifying risk and prevention of the clinical expression of Alzheimer’s disease. Nature Aging 2025, 5: 1930-1932. PMID: 40983695, DOI: 10.1038/s43587-025-00977-0.Peer-Reviewed Original ResearchCitationsAltmetricConceptsExpression of Alzheimer's diseaseClinical expression of Alzheimer's diseaseAlzheimer's diseaseInternational Working GroupCognitively unimpaired peopleUnimpaired peopleStratify riskWorking GroupClinical expressionPreventionGroup viewpointRiskDiseaseStratification frameworkDisease pathologyInternationalPeopleImplications of practice effects for the design of Alzheimer clinical trials
Duehring J, Jacobs D, Thomas M, Dodge H, Feldman H, Edland S. Implications of practice effects for the design of Alzheimer clinical trials. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2025, 11: e70154. PMID: 40936998, PMCID: PMC12420670, DOI: 10.1002/trc2.70154.Peer-Reviewed Original ResearchCitationsAltmetricConceptsNational Alzheimer's Coordinating CenterAnnual rate of changeAmnestic mild cognitive impairmentAmnestic mild cognitive impairment participantsOutcome measuresMagnitude of practice effectsAssessed prior to randomizationNational Alzheimer's Coordinating Center sampleUniform Data SetAlzheimer's disease clinical trialsRate of declineAnnual rateYears of follow-up dataComposite measureMild cognitive impairment participantsCognitively impaired participantsTrial designCoordinating CenterEarly-stage Alzheimer's diseaseRun-in designNatural history studiesPractice effectsMild cognitive impairmentLongitudinal cognitive declineLinear mixed effects modelsTranslation and cultural adaptation of tools to assess diverse Asian American and Asian Canadian subgroups: The Asian Cohort for Alzheimer's Disease (ACAD) Study
Lee H, Tzuang M, Chow T, Kang Y, Tee B, Li C, Lam E, Gu Y, Lee S, Ho P, Peavy G, Seo E, Kim K, Tran B, Chae W, Nguyen D, Vo N, Dang D, Spat‐Lemus J, Choi Y, Feldman H, Jun G, Wang L, Yu W, Park V, Study T. Translation and cultural adaptation of tools to assess diverse Asian American and Asian Canadian subgroups: The Asian Cohort for Alzheimer's Disease (ACAD) Study. Alzheimer's & Dementia 2025, 21: e70311. PMID: 40528300, PMCID: PMC12173839, DOI: 10.1002/alz.70311.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsCultural adaptationWorld Health OrganizationPromote health literacyCanadian older adultsAsian cohortCulturally appropriate translationCognitive assessment toolsLanguage backgroundAsian languagesAppropriate translationAssessment of cognitive functionHealth literacyStudy materialQuality healthcareCanadian adultsAlzheimer's diseaseTranslation processTranslation guidelinesOlder adultsSociocultural backgroundTranslation methodologyCanadian populationLanguage versionsAdaptation of toolsAssessment toolIWG and AA Criteria—Where the Differences Matter—Reply
Dubois B, Villain N, Feldman H. IWG and AA Criteria—Where the Differences Matter—Reply. JAMA Neurology 2025, 82: 629-630. PMID: 40257771, DOI: 10.1001/jamaneurol.2025.0772.Peer-Reviewed Original ResearchThe International Working Group recommendations on cognitively unimpaired individuals
Villain N, Frisoni G, Feldman H, Dubois B. The International Working Group recommendations on cognitively unimpaired individuals. The Lancet Neurology 2025, 24: 481. PMID: 40409306, DOI: 10.1016/s1474-4422(25)00162-0.Peer-Reviewed Original ResearchCitationsPrognostic value of plasma biomarkers for informing clinical trial design in mild-to-moderate Alzheimer’s disease
Qiu Y, Jacobs D, Messer K, Salmon D, Wellington C, Stukas S, Revta C, Brewer J, Léger G, Askew B, Donahue L, Kaplita S, Coric V, Qureshi I, Feldman H. Prognostic value of plasma biomarkers for informing clinical trial design in mild-to-moderate Alzheimer’s disease. Alzheimer's Research & Therapy 2025, 17: 97. PMID: 40317057, PMCID: PMC12046789, DOI: 10.1186/s13195-025-01745-3.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsMild to moderate ADADAS-cog11CDR-SBBaseline plasma NfLAlzheimer's diseasePlasma biomarkersMild-to-moderate Alzheimer's diseasePrognostic valueClinical trialsBaseline NfLPlasma NfLPlacebo-controlled trialCortical volumeConcentrations of plasma biomarkersMethodsPost hoc analysisDesign of clinical trialsClinical outcome dataIncreased ventricular volumeTrial participantsVolumetric MRIBaseline concentrationsEarly disease stagesClinical trial designTrial entry criteriaAD trialsExploring the usability and perceived benefits of Brain Health PRO: An online educational program for healthy brain aging
Philip G, Fiocco A, Belleville S, Chertkow H, Feldman H, Montero-Odasso M, Nygaard H, Savundranayagam M, Aging C. Exploring the usability and perceived benefits of Brain Health PRO: An online educational program for healthy brain aging. Digital Health 2025, 11: 20552076251395585. PMID: 41278371, PMCID: PMC12638707, DOI: 10.1177/20552076251395585.Peer-Reviewed Original ResearchConceptsOnline educational programOlder adultsModifiable dementia risk factorsCommunity-dwelling older adultsDementia risk factorsHealthy lifestyle behaviorsEducation programsWeeks of participationVirtual focus groupsBehavioral changesPersonal risk profileDementia riskLifestyle behaviorsPhysical activitySub-themesThematic analysisFocus groupsHealthy brain agingIntake questionnairePsychological healthBrain healthPositive experiencesRisk factorsHealthRisk profile
Get In Touch
Copy Link